Comparing the current results to its competitors, Abbott Laboratories reported Revenue increase in the 1 quarter 2026 by 7.78 % year on year. The revenue growth was below Abbott Laboratories's competitors' average revenue growth of 8.48 %, achieved in the same quarter.
Abbott Laboratories Net Income in the 1 quarter 2026 fell year on year by -18.72%, while most of its competitors have experienced a contraction in net income by -22.17 %.
Abbott Laboratories's Comment on Competition and Industry Peers
Abbott faces competition from both generic and branded companies that introduce additional forms of existing products. In the Diagnostic Products segment, competition is driven by technological innovation, price, convenience, service, warranty, product performance, laboratory efficiency, supply contracts, and cost-effectiveness. Abbott's technological advantages may diminish as competitors launch new products. In the Nutritional Products segment, competitors include diversified consumer and healthcare manufacturers, private label brands, and local manufacturers. Key competitive factors in this segment are consumer preferences, advertising, formulation, packaging, scientific innovation, price, retail distribution, and ingredient innovations. In the Medical Devices segment, competition arises from private label and local manufacturers, with additional pressures from new product introductions, changes in medical practices, and regulatory developments.
Ventyx Biosciences Inc is a biotechnology company that follows a research and development-focused business model. It aims to develop innovative biopharmaceutical products and therapeutic solutions by leveraging its expertise in various fields such as genetic engineering, drug discovery, and clinical trials. The company seeks to form strategic partnerships and licensing agreements to accelerate the commercialization of its products.
Jazz Pharmaceuticals Plc is a biopharmaceutical company focused on developing and commercializing innovative therapies for a range of medical conditions. Their business model revolves around conducting extensive research and development to identify novel molecules and compounds that can address unmet medical needs. By leveraging strategic partnerships, acquisitions, and licensing agreements, they aim to bring these therapies to market and provide valuable treatment options to patients worldwide.
Bausch Health Companies Inc operates through three segments: Bausch + Lomb/International, Salix, and Ortho Dermatologics. The company focuses on developing, manufacturing, and marketing a wide range of pharmaceutical products, medical devices, and over-the-counter products primarily in the areas of eye health, gastroenterology, and dermatology. Bausch Health aims to provide innovative and quality healthcare solutions to improve patients' lives globally.
Vertex Pharmaceuticals Incs business model centers on the research and development of innovative therapies, primarily targeting cystic fibrosis and other serious diseases. They emphasize collaboration with organizations, strategic partnerships, and robust investment in R&D to deliver transformative treatments to patients and enhance their quality of life.
Sources:
Abbott Laboratories’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Abbott Laboratories versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
